DK1137666T5 - GLP-1-analoger - Google Patents

GLP-1-analoger

Info

Publication number: DK1137666T5
Authority: DK; Denmark
Prior art keywords: analogues; glp; analogs; peptide; glucagon
Prior art date: 1998-12-07

Application number

DK99960657T

Other languages

English (en)

Other versions

DK1137666T3 (da

Inventor

David H Coy

Zheng Xin Dong

Original Assignee

Univ Tulane

Ipsen Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-07

Filing date

1999-12-07

Publication date

2009-10-05

1999-12-07 Application filed by Univ Tulane, Ipsen Pharma filed Critical Univ Tulane

2008-09-08 Application granted granted Critical

2008-09-08 Publication of DK1137666T3 publication Critical patent/DK1137666T3/da

2009-10-05 Publication of DK1137666T5 publication Critical patent/DK1137666T5/da

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
241000124008 Mammalia Species 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Cardiology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)

DK99960657T 1998-12-07 1999-12-07 GLP-1-analoger DK1137666T5 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11118698P	1998-12-07	1998-12-07
US20683398A	1998-12-07	1998-12-07
PCT/US1999/028929 WO2000034332A1 (en)	1998-12-07	1999-12-07	Glp-1 analogues

Publications (2)

Publication Number	Publication Date
DK1137666T3 DK1137666T3 (da)	2008-09-08
DK1137666T5 true DK1137666T5 (da)	2009-10-05

Family

ID=26808707

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99960657T DK1137666T5 (da)	1998-12-07	1999-12-07	GLP-1-analoger

Country Status (21)

Country	Link
US (2)	US7368427B1 (da)
EP (2)	EP1137666B9 (da)
JP (3)	JP2002538081A (da)
KR (1)	KR100458748B1 (da)
CN (2)	CN101108878B (da)
AT (1)	ATE394423T1 (da)
AU (1)	AU770609B2 (da)
BR (1)	BR9916027A (da)
CA (1)	CA2352573C (da)
CZ (2)	CZ303399B6 (da)
DE (1)	DE69938669D1 (da)
DK (1)	DK1137666T5 (da)
ES (1)	ES2302390T3 (da)
HU (1)	HUP0104579A3 (da)
IL (2)	IL143481A0 (da)
NO (2)	NO330293B1 (da)
PL (3)	PL205713B1 (da)
PT (1)	PT1137666E (da)
RU (1)	RU2208015C2 (da)
TW (2)	TWI339208B (da)
WO (1)	WO2000034332A1 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL205713B1 (pl) *	1998-12-07	2010-05-31	Sod Conseils Rech Applic	Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
WO2000034331A2 (en)	1998-12-07	2000-06-15	Societe De Conseils De Recherches Et D'applications Scientifiques Sas	Analogues of glp-1
EP1305338A2 (en) *	2000-08-02	2003-05-02	Theratechnologies Inc.	Modified peptides with increased potency
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002022151A2 (en) *	2000-09-18	2002-03-21	Osteometer Bio Tech A/S	Use of glp-1 and flp-2 peptides for treatment of bone disorders
WO2002034285A2 (en)	2000-10-20	2002-05-02	Coolidge Thomas R	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP1346722B1 (en)	2000-12-01	2008-12-10	Takeda Pharmaceutical Company Limited	Method for producing preparation containing bioactive substance
JP2005501058A (ja)	2001-07-31	2005-01-13	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンテッドバイザセクレタリーデパートメントオブヘルスアンドヒューマンサービシーズザナショナルインステ	Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
AU2012202081B2 (en) *	2001-07-31	2014-09-25	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	GLP-1 Exendin-4 peptide analogs and uses thereof
KR20040054729A (ko) *	2001-10-18	2004-06-25	브리스톨-마이어스 스큅 컴퍼니	인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1578778B1 (en) *	2002-07-23	2011-01-26	Ipsen Pharma	Ghrelin analogs
EP1583549A4 (en) *	2003-01-17	2006-10-04	Sod Conseils Rech Applic	YY PEPTIDE ANALOGS
WO2004074315A2 (en)	2003-02-19	2004-09-02	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Analogues of glp-1
CA2741545A1 (en) *	2003-03-28	2004-10-14	National Institute Of Agrobiological Sciences	Process for producing plant storage organ with high production of recombinant glp-1 and novel recombinant glp-1
US7008957B2 (en)	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094800B2 (en)	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en)	2003-07-28	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de)	2003-08-01	2005-02-03	Aventis Pharma Deutschland Gmbh	Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
EP1711523B1 (en)	2003-12-16	2012-10-10	Ipsen Pharma	Analogues of glp-1
CA2550695A1 (en) *	2003-12-16	2005-06-30	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Glp-1 pharmaceutical compositions
AU2005203925A1 (en) *	2004-01-08	2005-07-21	Theratechnologies Inc.	Glucagon-Like Peptide-1 analogs with long duration of action
US7534763B2 (en)	2004-07-02	2009-05-19	Bristol-Myers Squibb Company	Sustained release GLP-1 receptor modulators
TW200611704A (en) *	2004-07-02	2006-04-16	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CA2612063A1 (en) *	2005-06-13	2006-12-21	Imperial Innovations Limited	Oxyntomodulin analogues and their effects on feeding behaviour
WO2007051987A1 (en) *	2005-11-01	2007-05-10	Activotec Spp Limited	Insulinotropic compounds and uses thereof
EP2364735A3 (en)	2005-12-16	2012-04-11	Nektar Therapeutics	Branched PEG conjugates of GLP-1
AU2007240313B2 (en)	2006-04-20	2012-02-02	Amgen Inc.	GLP-1 compounds
WO2007139589A1 (en)	2006-05-26	2007-12-06	Bristol-Myers Squibb Company	Sustained release glp-1 receptor modulators
CN101578102B (zh) *	2007-01-05	2013-07-17	印第安纳大学研究及科技有限公司	在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
JP2010538069A (ja) *	2007-09-07	2010-12-09	イプセンファルマソシエテパールアクシオンサンプリフィエ	エキセンディン−４およびエキセンディン−３の類似体
TWI541023B (zh) *	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
WO2010076809A2 (en) *	2008-12-29	2010-07-08	Panacea Biotec Ltd	Glp-1 analogs and uses thereof
MX2012014576A (es) *	2010-06-24	2013-02-21	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida.
WO2012054861A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Pharmacologically active polymer-glp-1 conjugates
EP2713722B1 (en)	2011-05-31	2017-03-15	Receptos, LLC	Novel glp-1 receptor stabilizers and modulators
ES2836973T3 (es)	2011-12-12	2021-06-28	Receptos Llc	Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes
CN102584982B (zh) *	2012-02-10	2014-02-05	深圳翰宇药业股份有限公司	一种纯化固相合成利拉鲁肽粗肽的方法
JP6224586B2 (ja)	2012-07-10	2017-11-01	武田薬品工業株式会社	注射用製剤
AR096440A1 (es) *	2013-05-28	2015-12-30	Takeda Pharmaceuticals Co	Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
CN103285379A (zh) *	2013-06-09	2013-09-11	南方医科大学	Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途
BR112015031040A8 (pt)	2013-06-11	2018-01-02	Receptos Inc	Novos moduladores do receptor de glp-1
US9474755B2 (en)	2014-07-25	2016-10-25	Celgene International Ii Sarl	GLP-1 receptor modulators
JP2018012644A (ja) *	2014-11-26	2018-01-25	武田薬品工業株式会社	ペプチド化合物
CA2969944A1 (en)	2014-12-10	2016-06-16	Celgene International Ii Sarl	Glp-1 receptor modulators
HK1249847A1 (zh)	2015-03-09	2018-11-16	Intekrin Therapeutics, Inc.	用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
CR20180378A (es)	2015-12-23	2018-12-06	Amgen Inc	Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
EP3393496B1 (en)	2015-12-23	2023-10-11	The Johns Hopkins University	Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
EP3467106B1 (en)	2016-05-24	2025-07-09	Takeda Pharmaceutical Company Limited	Peptide compound
JP2019520336A (ja) *	2016-06-02	2019-07-18	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	水溶性で化学的に安定なグルカゴンペプチド
KR102781241B1 (ko)	2017-01-17	2025-03-14	암젠 인크	위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
KR20200036808A (ko)	2017-04-03	2020-04-07	코히러스 바이오사이언시스, 인크.	진행성 핵상 마비 치료를 위한 PPARγ 작용제
MX2019013919A (es)	2017-06-20	2020-01-21	Amgen Inc	Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja)	2017-06-21	2023-04-03	アムジエン・インコーポレーテツド	胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
CN109942696A (zh) *	2017-12-21	2019-06-28	中国药科大学	长效化胰高血糖素样肽－1（glp－1）类似物及其应用
CN116970062B (zh) *	2022-04-29	2024-04-09	南京知和医药科技有限公司	一种超长效glp-1多肽衍生物及其制备方法和用途
KR20250027558A (ko)	2022-06-23	2025-02-26	광저우 이노젠 파마슈티컬 그룹 컴퍼니 리미티드	개선된 glp-1 수용체 작용제 및 그 용도를 포함하는 융합 단백질
WO2024199491A1 (zh)	2023-03-30	2024-10-03	广州银诺医药集团股份有限公司	一种包含glp-1融合蛋白的药物制剂及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1539498A (en)		1925-05-26		And fifteen
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) *	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
WO1991011454A1 (en) *	1990-01-24	1991-08-08	The Upjohn Company	Method of purifying recombinant polypeptides
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
SK155694A3 (en) *	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5665702A (en)	1995-06-06	1997-09-09	Biomeasure Incorporated	Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
WO1997029180A1 (en) *	1996-02-06	1997-08-14	Eli Lilly And Company	Diabetes therapy
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
JP3149958B2 (ja) *	1996-08-30	2001-03-26	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ―１誘導体
US5916883A (en)	1996-11-01	1999-06-29	Poly-Med, Inc.	Acylated cyclodextrin derivatives
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998043658A1 (en) *	1997-03-31	1998-10-08	Eli Lilly And Company	Glucagon-like peptide-1 analogs
WO1999043705A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
FR2777283B1 (fr) *	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6720407B1 (en)	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
WO2000034331A2 (en)	1998-12-07	2000-06-15	Societe De Conseils De Recherches Et D'applications Scientifiques Sas	Analogues of glp-1
PL205713B1 (pl) *	1998-12-07	2010-05-31	Sod Conseils Rech Applic	Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
AU1269501A (en)	1999-11-12	2001-05-30	Novo Nordisk A/S	Use of glp-1 agonists for the inhibition of beta cell degeneration
CN114612953B (zh)	2020-12-09	2025-09-26	佳能株式会社	对象识别模型的训练方法及装置

1999
- 1999-12-07 PL PL349609A patent/PL205713B1/pl unknown
- 1999-12-07 AU AU17512/00A patent/AU770609B2/en not_active Ceased
- 1999-12-07 PL PL385112A patent/PL208751B1/pl unknown
- 1999-12-07 DE DE69938669T patent/DE69938669D1/de not_active Expired - Lifetime
- 1999-12-07 CN CN2007101410499A patent/CN101108878B/zh not_active Expired - Fee Related
- 1999-12-07 DK DK99960657T patent/DK1137666T5/da active
- 1999-12-07 HU HU0104579A patent/HUP0104579A3/hu unknown
- 1999-12-07 PL PL393611A patent/PL393611A1/pl unknown
- 1999-12-07 EP EP99960657A patent/EP1137666B9/en not_active Expired - Lifetime
- 1999-12-07 ES ES99960657T patent/ES2302390T3/es not_active Expired - Lifetime
- 1999-12-07 WO PCT/US1999/028929 patent/WO2000034332A1/en not_active Ceased
- 1999-12-07 BR BR9916027-7A patent/BR9916027A/pt not_active IP Right Cessation
- 1999-12-07 CA CA2352573A patent/CA2352573C/en not_active Expired - Fee Related
- 1999-12-07 CZ CZ20120110A patent/CZ303399B6/cs not_active IP Right Cessation
- 1999-12-07 JP JP2000586774A patent/JP2002538081A/ja active Pending
- 1999-12-07 CN CNB998141852A patent/CN100334109C/zh not_active Expired - Fee Related
- 1999-12-07 RU RU2001118839/04A patent/RU2208015C2/ru not_active IP Right Cessation
- 1999-12-07 AT AT99960657T patent/ATE394423T1/de active
- 1999-12-07 EP EP08005960A patent/EP1992641A3/en not_active Withdrawn
- 1999-12-07 CZ CZ20011895A patent/CZ303120B6/cs not_active IP Right Cessation
- 1999-12-07 PT PT99960657T patent/PT1137666E/pt unknown
- 1999-12-07 KR KR10-2001-7007050A patent/KR100458748B1/ko not_active Expired - Fee Related
- 1999-12-07 US US09/856,676 patent/US7368427B1/en not_active Expired - Fee Related
- 1999-12-07 IL IL14348199A patent/IL143481A0/xx unknown
2000
- 2000-01-07 TW TW095106593A patent/TWI339208B/zh not_active IP Right Cessation
- 2000-01-07 TW TW088121393A patent/TWI262925B/zh not_active IP Right Cessation
2001
- 2001-05-31 IL IL143481A patent/IL143481A/en not_active IP Right Cessation
- 2001-06-06 NO NO20012787A patent/NO330293B1/no not_active IP Right Cessation
2005
- 2005-10-13 JP JP2005298418A patent/JP2006077022A/ja active Pending
2008
- 2008-05-06 US US12/115,976 patent/US20090149378A1/en not_active Abandoned
2009
- 2009-08-14 JP JP2009188046A patent/JP2010001301A/ja active Pending
2010
- 2010-03-04 NO NO20100307A patent/NO20100307L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2000034332A1 (en)	2000-06-15
AU1751200A (en)	2000-06-26
JP2002538081A (ja)	2002-11-12
ES2302390T3 (es)	2008-07-01
NO20100307L (no)	2001-08-06
US7368427B1 (en)	2008-05-06
EP1137666B9 (en)	2009-04-01
JP2010001301A (ja)	2010-01-07
CN101108878B (zh)	2012-08-29
TWI262925B (en)	2006-10-01
TWI339208B (en)	2011-03-21
PL393611A1 (pl)	2011-05-09
IL143481A (en)	2010-02-17
RU2208015C2 (ru)	2003-07-10
DE69938669D1 (de)	2008-06-19
CZ303399B6 (cs)	2012-08-29
NO20012787D0 (no)	2001-06-06
NO20012787L (no)	2001-08-06
TW200628489A (en)	2006-08-16
AU770609B2 (en)	2004-02-26
PT1137666E (pt)	2008-06-02
PL208751B1 (pl)	2011-06-30
CZ303120B6 (cs)	2012-04-11
HUP0104579A3 (en)	2002-05-28
EP1992641A3 (en)	2009-07-29
CN101108878A (zh)	2008-01-23
DK1137666T3 (da)	2008-09-08
EP1137666B1 (en)	2008-05-07
ATE394423T1 (de)	2008-05-15
CN1342166A (zh)	2002-03-27
CA2352573C (en)	2012-04-10
IL143481A0 (en)	2002-04-21
CZ20011895A3 (cs)	2001-12-12
CN100334109C (zh)	2007-08-29
US20090149378A1 (en)	2009-06-11
BR9916027A (pt)	2001-08-28
CA2352573A1 (en)	2000-06-15
JP2006077022A (ja)	2006-03-23
NO330293B1 (no)	2011-03-21
KR20010102953A (ko)	2001-11-17
EP1137666A1 (en)	2001-10-04
EP1992641A2 (en)	2008-11-19
PL205713B1 (pl)	2010-05-31
KR100458748B1 (ko)	2004-12-03
HUP0104579A2 (hu)	2002-04-29

Publication	Publication Date	Title
DK1137666T3 (da)	2008-09-08	GLP-1-analoger
PT1137667E (pt)	2005-02-28	Analogos do glp-1
EA200300026A1 (ru)	2003-04-24	Аналоги глюкагоноподобного пептида-1
WO2004074315A3 (en)	2004-11-25	Analogues of glp-1
EA199800752A1 (ru)	1999-04-29	Пентафторбензолсульфонамиды и их аналоги
CO5090908A1 (es)	2001-10-30	Procedimiento para administrar peptidos insulinotropicos
EA199900645A1 (ru)	2000-04-24	Композиции для лечения распираторного дистресс-синдрома взрослых или респираторного дистресс-синдрома новорожденных, содержащие 3-(циклопропилметокси)-n-(3,5-дихлор-4-пиридинил)-4-(дифторметокси) бензамид и легочное поверхностно-активное вещество
DE59308848D1 (de)	1998-09-10	Anwendung von urodilatin bei lungen- und bronchialerkrankungen
EP2210900A3 (en)	2010-08-11	Analogues of GLP-1
CY1105721T1 (el)	2010-12-22	Δερματικοι αναισθητικοι παραγοντες
EP1359159A3 (en)	2004-07-21	Analogues of GLP-1
TW200740456A (en)	2007-11-01	GLP-1 pharmaceutical compositions
EA200100140A1 (ru)	2001-06-25	Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
SE8402199L (sv)	1984-10-23	Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
PT878195E (pt)	2002-09-30	Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
ES2188189T3 (es)	2003-06-16	Composiciones que comprenden derivados de acido fenil-amino-tiofeno-acetico para el tratamiento del sindrome de angustia respiratoria aguda o de adultos (ards) y del sindrome de angustia respiratoria de niños (irds).
AR021575A1 (es)	2002-07-24	Analogo de glp-1
UA88862C2 (en)	2009-12-10	Glucagon-like peptide-1 analogs
GEP20074097B (en)	2007-05-10	Use of specific dose of fondaparinux sodium for the treatment of acs